Skip to main content

Grafa News and Videos — Page 1464

Latest

Grafa

FDA grants priority review to Pfizer and Astellas for Padcev-Keytruda combo in MIBC

Pfizer (NYSE:PFE) and Astellas announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for the perioperative use of Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab).

Read more: FDA grants priority review to Pfizer and Astellas for Padcev-Keytruda combo in MIBC

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift